Develops novel treatments for neurodegenerative diseases using its proprietary nanocrystalline gold therapeutic platform.
Clene Inc., a dynamic clinical-stage pharmaceutical company headquartered in Salt Lake City, Utah, specializes in pioneering clean-surfaced nanotechnology (CSN) therapeutics. The company is dedicated to discovering, developing, and commercializing innovative treatments that harness the potential of nanotechnology for therapeutic benefits.
At the forefront of Clene's portfolio is CNM-Au8, its lead drug candidate currently undergoing multiple clinical trials. These include a Phase 2/3 registrational trial for amyotrophic lateral sclerosis (ALS), Phase 2 trials for visual pathway deficits in chronic optic neuropathy, and planned Phase 2 trials for Parkinson's Disease. The company's pipeline also features CNM-AgZn17, a gel polymer suspension aimed at treating infectious diseases and accelerating wound healing. Additionally, Clene is advancing CNM-ZnAg, a versatile antiviral and antibacterial agent targeting infections such as COVID-19, and CNM-PtAu7, a CSN therapeutic designed for oncology applications.
Founded on innovative science and driven by a commitment to addressing critical medical needs, Clene Inc. extends its impact beyond therapeutics to include dietary supplements like rMetx and KHC46. These supplements leverage aqueous zinc-silver and gold nanoparticles, respectively, to support health and well-being. Through strategic advancements in nanotechnology, Clene continues to position itself as a leader in the evolving landscape of pharmaceutical innovation and nanomedicine.